CRVS on Nasdaq

Corvus Pharmaceuticals, Inc.

American pharmaceutical preparations company based in Burlingame.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerCRVS on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersBurlingame, United States
Incorporated inDE²
Business address901 Gateway Blvd, Third Floor, South San Francisco, Ca 94080²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴⁵⁶⁷-$43.0M in 2025−12% since 2019

Net income³⁴⁵⁶⁷-$15.3M in 2025−67% since 2019

Every line of the income statement as filed: the last 3 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Research and development	$33.7M	$19.4M	$16.5M
General and administrative	$9.3M	$8.2M	$6.9M
Total operating expenses	$43.0M	$27.5M	$23.4M
Loss from operations	-$43.0M	-$27.5M	-$23.4M
Interest income and other expense, net	$2.5M	$1.8M	$1.6M
Gain from sale of property and equipment		$5.0K
Change in fair value of warrant liability	$27.1M	-$33.4M
Loss before equity method investment	-$13.3M	-$59.1M	-$21.7M
Loss from equity method investment	-$2.0M	-$3.2M	-$5.3M
Net loss	-$15.3M	-$62.3M	-$27.0M
Net loss per share, basic	-$0.19	-$1.02	-$0.56
Net loss per share, diluted	-$0.53	-$1.02	-$0.56
Shares used to compute net loss per share, basic	79.0M shares	61.0M shares	48.0M shares
Shares used to compute net loss per share, diluted	79.7M shares	61.0M shares	48.0M shares
Unrealized gain (loss) on marketable securities	-$17.0K	$65.0K	$66.0K
Cumulative foreign currency translation adjustment	$409.0K	-$386.0K	-$470.0K
Comprehensive loss	-$14.9M	-$62.6M	-$27.4M

Total assets¹⁰³⁴⁵⁶⁷$71.1M in 2025−15% since 2019

Total liabilities¹⁰³⁴⁵⁶⁷$9.9M in 2025−21% since 2019

Shareholders’ equity⁴⁵⁶⁷$61.2M in 2025−14% since 2019

Cash¹⁰³⁴⁵⁶⁷$4.6M in 2025−11% since 2019

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Cash and cash equivalents	$4.6M	$8.7M
Marketable securities	$52.2M	$43.2M
Accounts receivable	$37.0K	$75.0K
Prepaid and other current assets	$1.4M	$2.4M
Total current assets	$58.2M	$54.4M
Property and equipment, net	$220.0K	$151.0K
Operating lease right-of-use asset	$839.0K	$1.2M
Investment in Angel Pharmaceuticals	$11.0M	$12.5M
Other assets	$855.0K	$632.0K
Total assets	$71.1M	$68.9M
Accounts payable	$2.5M	$2.6M
Operating lease liability	$403.0K	$185.0K
Accrued and other liabilities	$6.5M	$3.7M
Warrant liability		$28.9M
Total current liabilities	$9.4M	$35.4M
Operating lease liability	$534.0K	$937.0K
Total liabilities	$9.9M	$36.3M
Common stock: $0.0001 par value; 290,000,000 shares authorized at December 31, 2025 and December 31, 2024; 74,696,629 and 67,899,779 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	$7.0K	$7.0K
Additional paid-in capital	$474.4M	$430.9M
Accumulated other comprehensive loss	-$896.0K	-$1.3M
Accumulated deficit	-$412.3M	-$397.0M
Total stockholders' equity	$61.2M	$32.6M	$38.7M	$56.1M
Total liabilities and stockholders' equity	$71.1M	$68.9M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	290.0M shares	290.0M shares
Common stock, shares issued	74.7M shares	67.9M shares
Common stock, shares outstanding	74.7M shares	67.9M shares

Period ending	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Cash and cash equivalents	$4.6M	$8.7M
Marketable securities	$52.2M	$43.2M
Accounts receivable	$37.0K	$75.0K
Prepaid and other current assets	$1.4M	$2.4M
Total current assets	$58.2M	$54.4M
Property and equipment, net	$220.0K	$151.0K
Operating lease right-of-use asset	$839.0K	$1.2M
Investment in Angel Pharmaceuticals	$11.0M	$12.5M
Other assets	$855.0K	$632.0K
Total assets	$71.1M	$68.9M
Accounts payable	$2.5M	$2.6M
Operating lease liability	$403.0K	$185.0K
Accrued and other liabilities	$6.5M	$3.7M
Warrant liability		$28.9M
Total current liabilities	$9.4M	$35.4M
Operating lease liability	$534.0K	$937.0K
Total liabilities	$9.9M	$36.3M
Common stock: $0.0001 par value; 290,000,000 shares authorized at December 31, 2025 and December 31, 2024; 74,696,629 and 67,899,779 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	$7.0K	$7.0K
Additional paid-in capital	$474.4M	$430.9M
Accumulated other comprehensive loss	-$896.0K	-$1.3M
Accumulated deficit	-$412.3M	-$397.0M
Total stockholders' equity	$61.2M	$32.6M	$38.7M	$56.1M
Total liabilities and stockholders' equity	$71.1M	$68.9M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	290.0M shares	290.0M shares
Common stock, shares issued	74.7M shares	67.9M shares
Common stock, shares outstanding	74.7M shares	67.9M shares

Cash from operations³⁴⁵⁶⁷-$32.8M in 2025−12% since 2019

Capital spending³⁴⁵⁶⁷$174.0K in 2025+596% since 2019

Free cash flow³⁴⁵⁶⁷-$33.0M in 2025−12% since 2019

Every line of the cash flow as filed: the last 3 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Net loss	-$15.3M	-$62.3M	-$27.0M
Depreciation and amortization	$105.0K	$85.0K	$151.0K
Accretion related to marketable securities	-$1.3M	-$1.1M	-$894.0K
Stock-based compensation	$5.3M	$3.0M	$2.1M
Gain from sale of property and equipment		-$5.0K
Change in fair value of warrant liability	-$27.1M	$33.4M
Loss from equity method investment	$2.0M	$3.2M	$5.3M
Prepaid and other current assets	$941.0K	-$1.6M	-$8.0K
Operating lease right-of-use asset	$338.0K	-$28.0K	$1.1M
Other assets	-$223.0K	-$543.0K	$40.0K
Accounts payable	-$91.0K	$1.1M	-$451.0K
Accrued and other liabilities	$2.8M	-$245.0K	-$3.6M
Operating lease liability	-$185.0K	-$252.0K	-$1.2M
Net cash used in operating activities	-$32.8M	-$25.4M	-$23.9M
Purchases of marketable securities	-$91.8M	-$70.1M	-$47.0M
Maturities of marketable securities	$84.1M	$42.6M	$62.6M
Purchases of property and equipment	-$174.0K		-$34.0K
Proceeds from sale of property and equipment		$5.0K
Net cash provided by (used in) investing activities	-$7.8M	-$27.5M	$15.5M
Proceeds from issuance of common stock, net (includes $1,794 in aggregate gross proceeds from related parties)		$16.4M
Proceeds from issuance of common warrants (includes $1,472 in aggregate gross proceeds from related parties)		$8.9M
Proceeds from the exercise of common stock warrants (includes $4,960 in aggregate gross proceeds from related parties for the year ended December 31, 2025)	$35.7M	$18.6M
Proceeds from issuance of common stock in connection with at-the-market offering, net			$7.8M
Proceeds from exercise of common stock options	$684.0K	$68.0K	$12.0K
Net cash provided by financing activities	$36.4M	$49.0M	$7.9M
Net decrease in cash and cash equivalents	-$4.2M	-$3.9M	-$539.0K
Reclassification of common stock warrant liability into additional paid-in capital upon exercise of common stock warrants	$1.8M	$13.4M
Right-of-use asset obtained in exchange for operating lease liability		$1.2M
Proceeds from issuance of pre-funded warrants		$5.0M

Compare Corvus Pharmaceuticals, Inc. with another company

Leadership

Who has led Corvus Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

20202025

Chief executive officerRichard A. Miller Md. Mar 22, 2016 to now¹¹
PresidentRichard A. Miller Md. Mar 22, 2016 to now¹¹
Chief financial officerLeiv Lea Mar 22, 2016 to now¹²

Board members and other officers (17)

Chief Business OfficerJeffrey Arcara Feb 8, 2024 to now¹³
Chief Medical OfficerMehrdad Mobasher Jan 30, 2019 to Dec 17, 2020¹⁴
EVP Discovery ResearchJoseph J. Buggy Jan 23, 2018 to Dec 16, 2019¹⁵
SVP, Chief Business OfficerDaniel W. Hunt Dec 15, 2017 to Dec 16, 2019¹⁶
V.P., Chemistry ResearchErik J. Verner Mar 22, 2016 to Dec 16, 2019¹⁷
SVP, Chief Business OfficerJason Coloma V. Jun 10, 2016 to Jun 10, 2016¹⁸
Board memberAndrew C. Chan Apr 27, 2026 to now¹⁹
Board memberEdith P. Mitchell Sep 15, 2020 to Dec 8, 2023²⁰
Board memberLinda S. Grais Jan 30, 2019 to now²¹
Board memberIan T. Clark Jan 4, 2017 to now²²
Board memberPeter A. Thompson Mar 22, 2016 to now²³
Board memberPeter Moldt Mar 22, 2016 to Mar 22, 2016²⁴
Board memberRichard A. Miller Md. Mar 22, 2016 to now¹¹
Board memberScott W. Morrison Mar 22, 2016 to now²⁵
Board memberSteve E. Krognes Mar 22, 2016 to Jun 12, 2020²⁶
Board memberTerry P. Gould Mar 22, 2016 to Jun 17, 2024²⁷
Board memberSamuel D. Isaly May 20, 2016 to Jun 27, 2016²⁸

Timeline

Mar 22, 2016New chief executive Richard A. Miller Md. becomes CEO¹¹
Jan 27, 2014Founded Corvus Pharmaceuticals, Inc. is founded²⁹

Filings

220 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 49 major events, 85 insider forms, 36 large holders, 30 other. The latest 20:

Aug 7, 2026SCHEDULE 13G EDGAR
Aug 6, 20268-K EDGAR
Aug 6, 202610-Q EDGAR
Jul 27, 2026SCHEDULE 13G/A EDGAR
Jul 22, 20268-K EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 15, 20264 EDGAR
Jun 12, 20268-K EDGAR
May 20, 20264 EDGAR
May 15, 2026SCHEDULE 13G/A EDGAR
May 15, 2026SCHEDULE 13G EDGAR
May 14, 20268-K EDGAR
May 7, 20268-K EDGAR
May 7, 2026S-8 EDGAR
May 7, 202610-Q EDGAR
Apr 27, 2026SCHEDULE 13G/A EDGAR
Apr 27, 20264 EDGAR

The 220 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 36 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Orbimed Advisors LLC	7,165,006	$107.0M	2.0%	No change
BlackRock, Inc.	7,138,811	$106.7M	0.0%	+978,389
State Street Corp	4,474,091	$66.8M	0.0%	+908,099
Vanguard Capital Management LLC	3,292,710	$49.2M	0.0%	+58,172
Adams Street Partners LLC	3,275,616	$48.9M	11.1%	No change
Vivo Capital, LLC	2,805,816	$41.9M	3.8%	No change
Wellington Management Group Llp	2,731,632	$40.8M	0.0%	+413,115
Perceptive Advisors LLC	2,667,441	$39.9M	0.6%	+375,000
Deep Track Capital, LP	2,491,939	$37.2M	0.5%	+400
Braidwell LP	2,126,298	$31.8M	1.2%	+373,500
Geode Capital Management, LLC	1,853,659	$27.7M	0.0%	+140,918
Foresite Capital Management VI LLC	1,831,233	$27.4M	4.3%	No change
Goldman Sachs Group Inc	1,576,352	$23.6M	0.0%	+35,543
Hood River Capital Management LLC	1,571,805	$23.5M	0.2%	+236,696
Morgan Stanley	1,344,736	$20.1M	0.0%	−1,154,089
Boxer Capital Management, LLC	1,100,000	$16.4M	1.2%	No change
Catalio Capital Management, LP	1,080,888	$16.1M	3.0%	+188,955
Millennium Management LLC	1,047,985	$15.7M	0.0%	+181,623
Vanguard Portfolio Management LLC	814,750	$12.2M	0.0%	+144,855
Two Sigma Investments, LP	785,208	$11.7M	0.0%	+245,339
Bank Of America Corp /de/	757,798	$11.3M	0.0%	+520,794
Adage Capital Partners Gp, L.l.c.	750,000	$11.2M	0.0%	No change
Eversept Partners, LP	747,994	$11.2M	0.6%	New
Emerald Advisers, LLC	685,683	$10.2M	0.2%	−533
DCF Advisers, LLC	637,500	$9.5M	2.5%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARCorvus Pharmaceuticals, Inc. filings on SEC EDGAR
2
SEC EDGARCorvus Pharmaceuticals, Inc. filings on SEC EDGAR
3
SEC EDGARCorvus Pharmaceuticals, Inc. 10-K for fiscal 2019
4
SEC EDGARCorvus Pharmaceuticals, Inc. 10-K for fiscal 2020
5
SEC EDGARCorvus Pharmaceuticals, Inc. 10-K for fiscal 2021
6
SEC EDGARCorvus Pharmaceuticals, Inc. 10-K for fiscal 2022
7
SEC EDGARCorvus Pharmaceuticals, Inc. 10-K for fiscal 2023
8
SEC EDGARCorvus Pharmaceuticals, Inc. 10-Q for fiscal 2026
9
SEC EDGARCorvus Pharmaceuticals, Inc. 10-Q for fiscal 2026
10
SEC EDGARCorvus Pharmaceuticals, Inc. 10-K for fiscal 2019
11
SEC EDGARRichard A. Miller Md., Chief executive officer
12
SEC EDGARLeiv Lea, Chief financial officer
13
SEC EDGARJeffrey Arcara, Chief Business Officer
14
SEC EDGARMehrdad Mobasher, Chief Medical Officer
15
SEC EDGARJoseph J. Buggy, EVP Discovery Research
16
SEC EDGARDaniel W. Hunt, SVP, Chief Business Officer
17
SEC EDGARErik J. Verner, V.P., Chemistry Research
18
SEC EDGARJason Coloma V., SVP, Chief Business Officer
19
SEC EDGARAndrew C. Chan, Board member
20
SEC EDGAREdith P. Mitchell, Board member
21
SEC EDGARLinda S. Grais, Board member
22
SEC EDGARIan T. Clark, Board member
23
SEC EDGARPeter A. Thompson, Board member
24
SEC EDGARPeter Moldt, Board member
25
SEC EDGARScott W. Morrison, Board member
26
SEC EDGARSteve E. Krognes, Board member
27
SEC EDGARTerry P. Gould, Board member
28
SEC EDGARSamuel D. Isaly, Board member
29
gleifCorvus Pharmaceuticals, Inc. is founded